tulin of plasma (CIg) are the main protein components of the heparin-precipitable fraction of normal plasma. The interactions among these proteins and heparin were examined. Heparin formed a cold-precipitable complex with purified CIg or with mixtures of CIg and fibrinogen but not with purified fibrinogen alone. Cryoprecipitation was augmented by addition of Ca++ or by selection of optimal heparin levels; it was reduced or even abolished by raising the ionic strength or pH or both, or by raising the heparin concentration above that for maximum precipitation of CIg.
Fibrinogen reduced the threshold for heparin-indtuced CIg cryoprecipitation and, by coprecipitating with heparin and CIg, increased the amount of precipitate that formed. In contrast to the heparin-precipitable fraction of normal plasma which contained both fibrinogen and CIg, that from a patient with congenital afibrinogenemia contained CIg but lacked fibrinogen. Normal plasma depleted of CIg by immunoabsorption failed to form a heparin-induced cryoprecipitate. Thus, CIg is essential for heparin-induced cryoprecipitation to occur. Fibrinogen, as assessed by chromatographic experiments with heparin-Sepharose columns, had a considerably lower binding affinity for heparin than did CIg, suggesting that it participates in precipitate formation mainly, if not entirely, by virtue of its affinity for CIg. The region of the fibrinogen molecule accounting for its precipitation with CIg appears to be localized in the carboxy-terminal segment of the Aa-chain; fibrinogen subfractions lack-
INTRODUCTION
In 1954, Thomas et al. (1) reported the occurrence of heparin-induced cryoprecipitates in plasma from endotoxin-treated rabbits. This fraction has come to be known as the "heparin-precipitable fraction of plasma." Subsequent studies by Smith and von Korff (2) and Smith (3) showed that large amounts of cryoprecipitate were formed from plasmas of patients with certain inflammatory, infectious, and neoplastic diseases to which heparin had been added. This phenomenon was also observed when heparin was added to the plasma of normal donors, but the amount produced was usually less (3, 4) . Smith and von Korff (2) found that cryoprecipitate formation was dependent upon heparin concentration and that it could be enhanced by the presence of divalent cations or reduced by increasing the temperature, ionic strength, or pH. They established that fibrinogen was a major component of this fraction. This conclusion was based upon the observations that the heparin-precipitable fraction was partially coagulable with thrombin, that a portion of it was similar to fibrinogen in electrophoretic and ultracentrifugal behavior (s2o,w, 7.9 to 8.3) , and that heparin-induced cryoprecipitation could not be produced in serum. They suggested that the fibrinogen in the precipitate might have been modified in some way because purified preparations of fibrinogen were only partially cryoprecipitable in the presence of heparin.
They also observed a second minor component of the fraction (s2o.w, 12 .5S) which they thought might be a form of fibrinogen, and they drew attention to its similarity to a component of normal plasma subfraction I-1 termed "cold-insoluble globulin" (5) . SubThe Journal of Clinical Investigation Volume 60 October 1977-855-865 855 sequent investigations of a patient with ovarian carcinoma (6) , and of plasma subfractions like fraction I-1, led to characterization of "cold-insoluble globulin", (CIg),1 as a normal plasma glycoprotein that is structurally and immunochemically distinct from fibrinogen and all other plasma proteins (7, 8) . CIg normally circulates at plasma levels of 0.33±0.1 g/liter (7); the level in serum is somewhat lower owing to incorporation of some of it into the fibrin clot (7, 9, 10), to which it can be covalently bound by factor XIIIa (10, 11).
Smith and von Korff's original speculation (2) (12) . Similar studies of dermatologic patients (13), although not employing immunochemical identification of CIg, have also permitted the same conclusion. However, it is not yet clear what role CIg plays in formation of the precipitate or what the relationship is between heparin-induced cryoprecipitates and those that form spontaneously in the cold without requiring addition of heparin (the latter type are popularly termed "cryofibrinogen"). Many studies since the classic report of Shainoff and Page (14) have indicated that most spontaneously occurring plasma cryoprecipitates contain fibrin in a complex with fibrinogen and perhaps with other proteins as well (6) . On the other hand, studies of the heparin-precipitable fraction from dermatologic patients (15) indicated that fibrinogen, but not fibrin, was a component of this type of cryoprecipitate.
To clarify some of the questions raised by studies cited above, we have undertaken a systematic investigation of the nature of plasma cryoprecipitates. The studies to be described in this report were designed to elucidate the mechanism offormation ofthe heparinprecipitable fraction ofplasma. We have focused particularly upon the interactions taking place among the major components of this fraction: CIg, fibrinogen, and heparin.
METHODS
Preparation and analysis offibrinogen and CIg. Fibrinogen subfractions 1-2, 1-4, 1-8, and I-9 were prepared from outdated human acid citrate dextrose plasma as previously described (16, 17) . Investigations of the amino terminal acids of these fractions (17, 18) have shown traces, at most, of glycine, an amino acid indicating the presence of fibrin in the preparation. The thrombin coagulability of each fraction was >95%. Purified human CIg was prepared by a modifica-'Abbreviation used in this paper: CIg, cold-insoluble globulin.
tion (19) of our original meth-d (7). The-concentfttions of purified fibrinogen and CIg were determined spectrophotometrically at pH 7 assuming absorption coefficients (A, cm) at 280 nm of 15.2 (20) and 12.8 (7), respectively.
CIg or fibrinogen concentration in plasma or related solutions was also determined by electroimmunoassay (21) on glass slides, 5 x 7 cm, coated with antibody-containing agarose in pH 8.6 barbital buffer (I, 0.05). Electrophoresis was carried out for 16 h at 60 V. The rabbit anti-human CIg serum was that previously reported (7) . Studies confirming the specificity of this antiserum for CIg have previously been reported (7, 19, 22, 23) . The rabbit anti-human fibrinogen serum had been prepared in this laboratory and was specific for fibrinogen (7) .
The fibrinogen used in these studies was free of detectable fibrin as assessed by the following criteria: when subjected to chromatography (24) on Sepharose 4B (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.), the fibrinogen emerged in a single symmetrical peak; the "ethanol gelation" test (25) was negative; no cryoprecipitate formned upon incubation at 2-4°C. Occasional preparations giving evidence of small amounts of "fibrin" or aggregates by one or more of the above criteria were subjected to chromatography at room temperature on a 0.9 x 25-cm fibrinogen-Sepharose affinity column (26) ; in such a system fibrin selectively binds to the column. After this additional treatment, the material met all the criteria described above for fibrinfree fibrinogen, and behaved in the same way as fibrinogen preparations not requiring such treatment.
The CIg contaminant (3-4% by electroimmunoassay) in fibrinogen fraction I-2 was reduced by diethylaminoethylcellulose gradient elution chromatography (7, 18) carried out at room temperature. In this chromatographic system, fibrinogen is eluted in two main peaks, the first of which ("peak 1") represents approximately 85% of the total fibrinogen in the fraction (27) , and emerges considerably before the CIg peak (7). Material CIg-depleted plasma prepared by either procedure behaved in a similar way in the experiments to be described. Procedures involving heparin. Several preparations of heparin were used and included a liquid preparation for intravenous administration (Na salt, Upjohn Co., Kalamazoo, Mich.; specific anti-coagulant activity 100 U. S. Pharmacopeia U/mg) and two heparin preparations in powdered form (Li salt, grade IV, 158 U. S. Pharmacopeia U/mg, and Na salt, grade I, 158 U. S. Pharmacopeia U/mg, Sigma Chemical Co., St. Louis, Mo.). The heparin preparation used in any given experiment was the Upjohn product unless otherwise indicated.
The rate and extent of cryoprecipitation of plasma samples or mixtures of CIg and fibrinogen were monitored spectrophotometrically in 1-ml cuvettes as follows: CIg-fibrinogen mixtures (initial volume usually <0.2 ml) were adjusted to a final volume of 1 ml with 0.05 M sodium phosphate-0.1 M NaCl buffer, pH 7.2 (I, 0.2); plasma samples were diluted 1:2 with this buffer. For experiments involving determination of the effect of Ca++, a 0.05 M Tris-HCl, 0.1 M NaCl, pH 7.2 buffer (I, 0.15) was used. The filled cuvettes were placed in a Gilford spectrophotometer (model 240; Gilford Instrument Laboratories Inc., Oberlin, Ohio). The temperature of the jacketed cuvette chamber was maintained at 2°C, and the formation of precipitate (i.e., increase in light scattering) followed by absorbance measurements at 350 nm. The readings obtained for heparin-containing mixtures were corrected by using as a blank a sample of the same mixture incubated under the same conditions without added heparin. Elevations in blank readings during the course of an experiment were small (0.030 or less). The heparininduced precipitate forming during the first 5 h in the absence of Ca++ was too fine to appreciate the presence of any discrete particles; there was no tendency for the precipitates to settle out unless subjected to centrifugation. Maximal light scattering under most experimental conditions usually developed within 1 h and always within 3 h of incubation. Unless otherwise specified, we reported only the reading taken at 3 h. The curves were very reproducible for any given set of conditions.
The heparin-precipitable fraction from fresh normal or afibrinogenemic plasma was obtained by incubating 1-10 ml of plasma in thle presence of heparin at 2-4°C for 16 h. The precipitate that formed was harvested at 40C by centrifugation at 10,000g for 30 min, extracted three times at 40C with 0.15 M NaCl-0.05 M Tris-HCl buffer, pH 7.2 (I, 0.2), resuspended in the same buffer, and brought into complete solution by incubation for 20 min to 2 h at 37°C. Without the addition of heparin, no such precipitate could be recovered from normal or afibrinogenemic plasma.
For the chromatographic experiments described below, the heparin-precipitable fraction from 140 ml fresh frozen acid citrate dextrose plasma (prepared with the Li or Na heparin preparations at a final concentration of 0.10 mg/ml) was extracted once with ice-cold 0.05 M Tris-phosphate buffer, pH 7 (I, 0.1), and then dissolved at 370C in 0.25 M Trisphosphate buffer, pH 7. To recover the heparin precipitated with this fraction, the dissolved fraction was diluted with water to a phosphate concentration of -0.05 M and then applied to a diethylaminoethyl-cellulose (DE-23, Whatman, Inc., Clifton, N. J.) column (0.9 x 30 cm) that had previously been equilibrated with 0.05 M Tris-phosphate buffer, pH 7. The column was flushed with additional 0.05 M Trisphosphate buffer until the absorbance at 280 nm had returned to near the base line. Protein remaining adsorbed to the column was then eluted stepwise with Tris-phosphate buffers of increasing molarity to remove first the fibrinogen-enriched (0.09 M) and then the CIg-enriched (0.2 M) fractions, respectively (7, 19) . After this, the column was flushed with 0.5 M NaCl to displace phosphate ions and remove any residual protein that remained. The heparin adsorbed to the column was then desorbed with 2 M LiCl (28) . Heparin concentration was determined by a modification (28) of the Azure A method of Jaques et al. (29) , with starting heparin as the standard. The anticoagulant activity of the heparin in the LiCl eluate peak was determined in platelet-poor citrated plasma by a thrombin time method (30) ; the activity, expressed in U. S. Pharmacopeia units, was based upon the reported anticoagulant activity of the starting heparin.
Heparin (Li salt) was coupled to Sepharose 4B as described by Miller-Anderson et al. (31) . The amount of heparin that had been coupled was determined after hydrolysis of heparin-agarose gel samples (32) by the phenolsulfuric acid method (33) and was found to be 12 mg/ml gel. Stepwise elution chromatography on a heparin-Sepharose column (0.9 x 25 cm) was carried out at room temperature or at 3±°C at a flow rate of 16 take place until after CIg had been added (Fig. 2) . The threshold CIg concentration for heparin-induced cryoprecipitation was markedly lower when fibrinogen was present and the amount of precipitate that formed was greater. This behavior was a clear indication that both CIg and fibrinogen had participated in the cryoprecipitation phenomenon. However, the amount of precipitate forming at this heparin level (0.05 mg/ml) increased only up to a CIg concentration of 300 ,ug/ml, as had been the case in the previous experiment without fibrinogen (Fig. 1) . This suggested that it was the amount of heparin, rather than fibrinogen, that determined the maximum amount of CIg in the cryoprecipitate. As was the case with heparin-CIg cryoprecipitates, the heparin-CIg-fibrinogen precipitate could be completely dissolved by incubation at 37°C.
The effect of heparin concentration. The effect of heparin concentration on precipitation of purified CIg or CIg-fibrinogen mixtures was examined further (Fig.  3) . Under any given set of buffer conditions favorable to precipitation, there was always an optimal range of heparin concentration at which maximum precipitation was achieved. When the heparin concentration was raised above the optimum level, the amount of precipitate progressively decreased. The shape of the precipitation curve of CIg-fibrinogen mixtures was the same as that of CIg alone, but the amount of precipitate at any given heparin concentration was greater in the presence of fibrinogen. In the experiment shown, the optimal heparin concentration range for precipitation of CIg was somewhat higher than it was for the CIg-fibrinogen mixture. Because the optimum level of heparin is dependent upon the CIg concentration (Figs.  1, 2 The effect of ionic strength, pH, and CaCl. The effects of ionic strength and pH on CIg cryoprecipitation were examined (Fig. 4) . The amount of heparininduced CIg cryoprecipitation decreased rapidly with increasing ionic strength or pH and was completely abolished at an ionic strength above 0.3 or at a pH above 9.0. At an ionic strength of 0.05 or lower at pH 7.0 or less, CIg was precipitated at 2°C in the absence of heparin. The effect of CaCl2 on cryoprecipitation was also assessed (Fig. 5) . Its addition greatly increased the amouint of precipitation that occurred in heparin-CIg or heparin-CIg-fibrinogen mixtures and resulted in more rapidly forming and more coarsely grantular precipitates which, although ultimately soluble at 37°C, did not redissolve as rapidly as did precipitates formed without added CaCl2. The addition of CaCl2 had no effect on CIg solutions lacking heparin or on fibrinogen-heparin mixtures lacking CIg. Consistent with this last observation, both heparin-CIg and heparin-CIg-fibrinogen mixtures showed a similar pattern of augmented precipitation in response to increasing CaCl2 concentration, suggesting that the CaCl2 effect is upon the heparin-CIg interaction.
The effect offibrinogen catabolites. Human plasma fibrinogen fractions [1] [2] [3] [4] [5] [6] [7] [8] have been shown Aa-chain (17) . Fraction 1-4, on the other hand, is comspecies, virtually prised of less extensively catabolized fibrinogen inal portion of the species characterized by the presence of a very high proportion of intact Aa-chains. Heparin-indtuced cryoprecipitation of CIg in the presence of these subfractions was compared (Fig. 6) . In contrast to the CIg-fraction 1-4 mixture which, as expected, developed a much greater amount of precipitate than did CIg alone, the cryoprecipitate forming in the CIg-fraction 1-8 and CIg-fraction I-9 mixtures differed only slightly from that of CIg alone.
Cryo precipitation of normal, afibrinogeneinic, and CIg-depleted plasma. Heparin-induced cryoprecipitation was carried out on normal plasma, that from an afibrinogenemic patient, or on normal plasma depleted of CIg (Fig. 7) . CIg-depleted plasma exhibited only a slight increase in light scattering during the course of the experiment, whereas afibrinogenemic 0.20 0.25 plasma developed a considerable amount of cryoprecipitate. Normal plasma yielded the greatest amount.
As expected, the heparin-precipitable fraction harvested from fresh normal plasma was partially coagula- 8.5 9.0 ble with thrombin, whereas that from afibrinogenemic plasma was not. fh and pH on heparin-
In related experiments, the optimal heparin level n (2°C) of CIg (225 for CIg cryoprecipitation of normal or afibrinogenemic pH dependence, the plasma was evaluted. Plasma was incubated with FIGURE 6 Heparin-induced cryoprecipitation of CIg (180 ,ug/ ml) in the absence or presence of fibrinogen fraction 1-4 (700 ,g/ml), I-8 (790 ,ug/ml), or I-9 (660 ,ug/ml). Heparin concentration, temperature, and buffer conditions were those given in the legend to Fig. 1 .
was similar to that observed in mixtures of heparin with purified CIg or with CIg plus fibrinogen. That is, the amount of precipitate that formed at suboptimal heparin levels increased as a function of heparin concentration, whereas precipitation was progressively decreased at heparin levels exceeding those for maximum precipitation. The optimal heparin level for CIg precipitation in normal plasma (CIg level, 310 ,ug/ml) was between 0.15 and 0.25 mg/ml, and resulted in precipitation of 88% or more of the plasma CIg. This was also the optimal range observed for heparinCIg mixtures at a comparable CIg level (Fig. 3) . Afibrinogenemic plasma required a somewhat higher heparin concentration (-0.50 mg/ml) for maximum -precipitation-; probaby -reflecting-the -relatively higher level of CIg in this plasma (540',ug/ml).
Further characterization of normal or afibrinogenemic plasma was made by dodecyl sulfate gel electrophoretic analysis of the heparin-precipitable fraction (Fig. 8) (Fig. 8) . In contrast, the afibrinogenemic heparin precipitate lacked the major fibrinogen band. In both samples, material with a slower migration rate than the CIg band of mol wt 450,000 probably represented noncovalent aggregates of CIg (23) . Reduced samples of the heparin precipitate from normal plasma showed the characteristic band pattern of fibrinogen (i.e., bands corresponding to the Aa, B,3, and y chains, respectively) and a major high molecular weight band corresponding to the position occupied by reduced CIg subunits (not shown). The reduced afibrinogenemic precipitate possessed only the major CIg band. Because of aggregation observed in unreduced norinal plasma samples (Fig. 8) , densitometric analyses were not attempted on such specimens. However, the relative proportion of CIg and fibrinogen in the precipitate from such plasma was assessed by densitometric scanlower molecular weight components bearing CIg antigenic determinants have also been described (23) .
3Upon dodecyl sulfate electrophoresis, unreduced fractions 1-4 or I-2 are resolved into two major bands, designated I and II (35) . These bands differ with respect to their Aa-chain populations. Band I contains molecules with a very high proportion of intact Aa-chains. In band II, a considerable proportion of the intact Aa-chains are replaced by a remnant chain termed Aa/4; this Aa-remnant lacks a carboxy-terminal peptide having a mol wt of approximately 13, 200 (calculated from the difference in size between Aa, 70,900, and Aa/4, 57,700; [35] ). Unreduced fractions 1-8 and I-9 display bands with more rapid anodal migration rates than band II; this is due to the fact that the average size of the Aa-remnant chains comprising these fractions is even smaller than those of molecules migrating in band II. Anticoagulant activity of heparin in the heparinprecipitable fraction. It is well known that heparin preparations consist of a group of closely related polydisperse glycosaminoglycans (36) (37) (38) (39) . Recent studies by Lam et al. (28) have shown that selective antithrombin-heparin cofactor binding activity is possessed by heparin molecules having a high specific anticoagulant potential. By utilizing this observation, they have been able to prepare heparin with specific anticoagulant activity of 348-388 U. S. Pharmacopeia U/mg from starting material with a sp act of only 155 U. S.
Phaumacopeia U/mg. Others have reported similari findings (40, 41) . To investigate whether heparin molecules possessing high anticoagulant activity have a special affinity for the protein components in the heparinprecipitable fraction, we determined the specific anticoagulant activity of heparin recovered by chromatography from the heparin precipitate of fresh-frozen normal plasma and that recovered by chromatography of starting heparin. The sp act of heparin recovered from the precipitate (accounting for 1 1 --12% of -the heparin added) was found to be 147 U. S. Pharmacopeia U/mg, a value slightly less than that of the starting material (158 U. S. Pharmacopeia U/ml) but virtually the same as heparin that had been subjected directly to the same chromatographic recovery procedures (151 U. S. Pharmacopeia U/mg).
Adsorption of CIg to a heparin affinity column. To better delineate the temperature-dependent nature of heparin-CIg complex formation and to investigate other variables, such as ionic strength and pH, that influence its formation, we studied the adsorption behavior of CIg on a heparin-Sepharose column at 4°C and at room temperature. Under the buffer and temperature conditions we used, there was no significant binding of CIg or fibrinogen to Sepharose alone. However, with a heparin-Sepharose column, approximately 87% of the CIg (1.2 mg) applied in buffer A was adsorbed at 40C. No additional CIg was eluted when the temperature of the system was allowed to rise to room temperature but an additional 41% was desorbed with buffer B at room temperature. The remainder was subsequently eluted by buffer C. Desorption could also be brought about at room temperature or even at 4°C by using buffers of higher pH. In a related experiment, CIgpoor fibrinogen prepared from fraction I-2 was applied to the column under the same conditions (1.5 mg protein; buffer A; 40C); only 7% was retained.
Binding experiments were also carried out with normal plasma applied to the heparin-Sepharose column in buffer A (Fig. 9) . Under the experimental conditions illustrated, 13% of the absorbance of the plasma, including 54% of the CIg and 2-4% of the fibrinogen, was retained by the column. The fibrinogen and CIg were subsequently recovered in the buffer C eluate peak. Dodecyl sulfate gel electrophoresis of material from this peak revealed numerous bands. One of these, a relatively weak staining band, had an anodal migration rate corresponding to that of CIg in reduced or unreduced samples. No further attempt was made in these experiments to characterize other bands in this fraction.
DISCUSSION--
Several previous studies, including that on a patient with ovarian carcinoma (6) , have suggested that the main nonclottable component of the heparin-precipitable fraction, first clearly described by Smith and von Korff (2) , would prove to be CIg. Indeed, Fyrand and Solum (12) and Matsuda et al. (13) have recently provided evidence that this is the case; our present studies confirm their conclusion. Fyrand and Solum did not specifically direct their attention toward defining the nature of the interactions of the main components of this fraction, but based upon the reported affinity of fibrinogen or fibrin for heparin (42, 43) , they suggested that it is the interaction between fibrinogen and heparin that is crucial for formation of the fraction (12) ;. e2s
J, rS TLJBE NUMU M .
FIGURE 9 Characteristics of normal plasma applied to a heparin-Sepharose column. The 3-ml plasma sample (fibrinogen concentration 2.4 mg/ml, CIg concentration 280,tg/ml) was diluted to 10 ml with buffer A and applied to the column at room temperature. (52, 53) . However, fibrinogen preparations are usually heavily contaminated with CIg (9, 11, and this study), and this fact has not been taken into account in certain experiments cited above whose proper interpretation wouild require differentiating effects due to indirect heparin binding of fibrinogen via CIg, from those due to direct binding. In any case, heparinfibrinogen complexes are probably not stable under ionic strength and pH conditions in the physiologic range (47) .
Heparin is known to be capable of binding several plasma proteins (51, 54, 55) , including thrombin (46, 51, 56, 57) and certain other coagulation factors (46, 48) , and an inhibitor known as antithrombin-heparin cofactor (46, 48, 57, 58) . The results of our electrophoretic analyses of material from plasma that had been retained on a heparin-Sepharose column are consistent with those observations, in that several electrophoretic bands were found, including the minor one corresponding to CIg (Fig. 9) . The numerous proteins binding to the heparin affinity column serve to underscore one of the unique features of the heparinCIg interaction, namely, that of all the heparinprotein complexes formed in plasma, only that between
CIg and heparin appears to be cold-insoluble to any appreciable extent. That is, the relatively intense staining of the CIg band in the heparin-induced cryoprecipitate of normal or afibrinogenemic plasma is quite impressive wlhen compared with its relatively weak intensity in the eluate fraction of the heparin affinity column (cf. Figs. 8 and 9 ). This fact, plus the discovery that plasma CIg can be precipitated in high yield in the presence of optimal amounts of heparin, offers a promising new first step in the purification of CIg which should result in a much higher recovery of material than can be obtained by application of presently existing preparative methods (7, 11, 19) . Furthermore, although a relatively simple ammonium sulfate precipitation method has been described (59) that can be used to prepare band I fibrinogen essentially free of fibrinogen catabolites, the use of heparin for this purpose introduces a new and simple way to obtain such molecules directly from plasma.
The antithrombin-heparin cofactor has an affinity for those heparin molecules possessing high anticoagulant activity (28, 40, 41) . This discovery provides a convenient means for separating heparin molecules with low anticoagulant potential from those with high potential. In our analysis of the heparin in the heparin-precipitable fraction, we observed that the specific anticoagulant activity of heparin recovered in this fraction was almost the same as that of the starting heparin. Failure to recover heparin of substantially higher or lower specific activity under precipitation conditions in which heparin was in molar excess with respect to CIg (heparin/CIg ratio 13-14:1) indicates that, unlike the plasma antithrombin-heparin cofactor, the heparin binding components of the heparin-induced precipitate are not selective for heparin molecules possessing high or low anticoagulant potential. This result is not surprising inasmuch as Smith and von Korff (2) were able to induce cryoprecipitation with a number of different sulfated polysaccharides that had little or no anticoagulant potential. Furthermore, they observed optimal precipitation in plasma at a heparin level in the same concentration range as we found in this study, although the specific anticoagulant activity of their preparation was not more than 1/10 that of the preparations we used.
It is widely appreciated that fibrinogen is a major and constant constituent of the heparin precipitate of normal as well as of pathological plasma (2, 3, 13, 15) . Certain early observations led to the inference that the fibrinogen in the fraction might have been altered in some way (2) , perhaps by having been converted to a form of fibrin. Inasmuch as fibrin can circulate in a soluble form in blood under pathological conditions (14) , and perhaps, to a limited extent, even in normal subjects (60) , it might be included as a significant component of the heparin-precipitable fraction under proper circumstances. Nevertheless, our present studies support those of Fyrand et al. (15) (35, 59, 61) (-13,200 ) between the intact Aa chain and the principal Aa chain remnant characterizing band II fibrinogen. 6 The carboxy-terminal region of the Aa chain also contains a site(s) that is utilized during factor XIIIacatalyzed cross-linking of fibrin a chains (62) (63) (64) , and possibly during cross-linking with CIg (11) as well.
